Reverse phase protein array is a high-throughput technology that performs protein assays on thousands of samples simultaneously, including tissue and cell lysates, serum, plasma or other body fluids.

GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (THER) (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast ...

Predicting cancer dependencies from molecular data can help stratify patients and identify novel therapeutic targets. Recently available data on large-scale cancer cell line dependency allow a ...

Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase ...

GOLDEN, Colo., Nov. 7, 2022 /PRNewswire/ -- Theralink Technologies (THER), Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for ...

RICHMOND, VIRGINIA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- The Virginia Innovation Partnership Corporation (VIPC) today announced that George Mason ...

Development of Machine Learning Algorithms Incorporating Electronic Health Record Data, Patient-Reported Outcomes, or Both to Predict Mortality for Outpatients With Cancer Advances in biological ...

The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite ...

Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding from Georgiamune, Inc., for a project in which Georgiamune, Inc., will provide cell ...